Vulvar lichen sclerosus: a study of markers Ki-67 and p53 before and after the treatment with clobetasol at 0.05%, testosterone at 2% and a placebo

The study targeted 30 patients diagnosed Vulvar LichenSclerosus, divided in three groups which made topical use of clobetasol propionate at 0.05 per cent, testosterone at 2 per cent and a placebo, so as to assess the evolution of the symptoms and the behavior of the cells marked with antibody Ki-67 and protein p53, before and after the treatments. We have noted positive evolution of the clinical symptoms in patients under the administration of clobetasol and testosterone, which proved statistically higher than the placebo (p<0.01). A significant decrease of the number of cells marked with Ki-67 and protein p53 was noted after the treatment with clobetasol and testosterone, whereas patients under the placebo revealed an increase of the cellular markers...